

Paxlovid 處方經驗分享

黃景泰 醫師

內科部感染醫學科

林口長庚醫院

Population

This recommendation applies only to people with these characteristics:




Disease severity

Non-severe	Severe	Critical
Absence of signs of severe or critical disease	Oxygen saturation <90% on room air Signs of pneumonia Signs of severe respiratory distress	Requires life sustaining treatment Acute respiratory distress syndrome Sepsis Septic shock



Therapeutics and COVID-19: living guideline
v10.0 published on 2022/4/22

<https://www.who.int/teams/health-care-readiness/covid-19/therapeutics>



 Therapeutics and COVID-19: living guideline
v10.0 published on 2022/4/22
<https://www.who.int/teams/health-care-readiness/covid-19/therapeutics>

PATIENT DISPOSITION

Does Not Require Hospitalization or Supplemental Oxygen

PANEL'S RECOMMENDATIONS

All patients should be offered symptomatic management (AIII).

For patients who are at high risk of progressing to severe COVID-19,^a use 1 of the following treatment options:

Preferred Therapies

Listed in order of preference:

- Ritonavir-boosted nirmatrelvir (Paxlovid)^{b,c} (AIIa)
- Remdesivir^{c,d} (BIIa)

Alternative Therapies

For use ONLY when neither of the preferred therapies are available, feasible to use, or clinically appropriate. Listed in alphabetical order:

- Bebtelovimab^e (CIII)
- Molnupiravir^{c,f} (CIIa)

The Panel **recommends against** the use of dexamethasone^g or other systemic corticosteroids in the absence of another indication (AIII).

	Paxlovid		Molnupiravir	
	EPIC-HR		MOVE-OUT	
	2,246		1,433	
Hospitalization(Death)	28 days		29 days	
Interim	0.77%(0) [7.01%(7)]	-89.1%	7.3% [14.1%]	-50%
Final	0.72%(0) [6.45%(9)]	-88.9%	6.8%(1) [9.7%(9)]	-30%
2ndary Endpoint				
Viral Load(5 th d)	-0.86 Log		-0.3 Log	
Adverse Events				
All	22.6 (23.9)%		30.4 (33.0)%	
Related to Drug	7.8 (3.8)%		8.0 (8.4)%	
DC due to AE due to drug	0.8 (0.6)%		0.6 (0.4)%	

Hammond J, et al. N Engl J Med. 2022;386:1397-1408.
 Jayk Bernal A, et al. N Engl J Med. 2022;286:509-20.

倍拉維

Paxlovid

Nirmatrelvir(150) 2#/Ritonavir(100) 1# q12h x 5 Days



參閱[Liverpool COVID-19 Interactions](#); IDSA guideline; Paxlovid藥品說明書

!	絕對禁用	<ul style="list-style-type: none"> 抗心律不整 Amiodarone
	停藥可用	<ul style="list-style-type: none"> 降血脂 Statins (Fluvastatin除外) 抗精神病 Clozapine 鎮靜安眠 Midazolam 支氣管擴張 Salmeterol 腸胃 Domperidone 偏頭痛 Ergotamine
	不太能停 需考慮	<ul style="list-style-type: none"> 抗凝血 Apixaban Rivaroxaban 抗血小板 Clopidogrel 抗癲癇 Clonazepam 鎮靜安眠 Diazepam 免疫調節劑 Cyclosporine Everolimus
	調整劑量 並監測	<ul style="list-style-type: none"> 心血管 CCB Digoxin Warfarin Dabigatran 精神醫學 Trazodone Bupropion Risperidone Quetiapine
	輕微交互作用 安全可用	<ul style="list-style-type: none"> Valproate Fluoxetine Clindamycin Losartan Ethinyl estradiol
	無交互作用 安全可用	<ul style="list-style-type: none"> Aspirin Bisoprolol Allopurinol Prednisolone PPI DM用藥

[UpToDate®](#)

Lexicomp® Drug Interactions

Add items to your list by searching below.

ITEM LIST

Clear List

Analyze

Paxlovid

Methotrexate

Labetalol

Pitavastatin

Tramadol-Acet [DSC] (CAN)

Vildagliptin and Metformin

Folic Acid

Exforge HCT

Etanercept

CAN: Canadian brand name
DSC: Discontinued brand (equivalent product[s] may be available)

Display complete list of interactions for an individual item by clicking item name.

NOTE: This tool does not address chemical compatibility related to I.V. drug preparation or administration.

X

Avoid combination

C

Monitor therapy

A

No known interaction

D

Consider therapy modification

B

No action needed

More about Risk Ratings

9 Results

C	Exforge HCT (AmlODIPine) Paxlovid (CYP3A4 Inhibitors (Strong))
C	Exforge HCT (Diuretics) Tramadol-Acet [DSC] (CAN) (Opioid Agonists)
C	Tramadol-Acet [DSC] (CAN) (Hypoglycemia-Associated Agents) Vildagliptin and Metformin (Antidiabetic Agents)
C	Tramadol-Acet [DSC] (CAN) (TraMADol) Paxlovid (Ritonavir)
C	Vildagliptin and Metformin (Antidiabetic Agents) Exforge HCT (Hyperglycemia-Associated Agents)
C	Vildagliptin and Metformin (Antidiabetic Agents) Exforge HCT (Thiazide and Thiazide-Like Diuretics)
C	Vildagliptin and Metformin (Antidiabetic Agents) Paxlovid (Hyperglycemia-Associated Agents)
B	Pitavastatin Paxlovid (Ritonavir)
A	Methotrexate Folic Acid


DISCLAIMER: Readers are advised that decisions regarding drug therapy must be based on the independent judgment of the clinician, changing information about a drug (eg, as reflected in the literature and manufacturer's most current product information).

Population

This recommendation applies only to people with these characteristics:




Disease severity



Therapeutics and COVID-19: living guideline

v10.0 | published on 2022/4/22

<https://www.who.int/teams/health-care-readiness/covid-19/therapeutics>



Paxlovid 副作用與安全性

• 副作用

- 味覺異常 Dysgeusia
- 腹瀉 Diarrhea

今(5/10)日起

口服抗病毒藥物開立表單簡化

表單名稱	說明
病人治療同意書	<ul style="list-style-type: none">● 居家照護者，以「病歷加註知情同意相關字樣」代替紙本同意書● 醫院、集檢所：可自製同意書格式，不限定用CDC版本
口服抗病毒藥物申請暨領用檢核表	免填、免繳回；改以健保代碼上傳 U071
口服抗病毒藥物領用切結書	<ul style="list-style-type: none">● 處方醫師、調劑藥局免填● 跨院所/跨藥局領用才需填寫
病人治療紀錄表	處方醫師免填，後續照護團隊可參考(非必填)

2022/05/10

中央流行疫情指揮中心



謝謝!